Share
By adolescence, most of our adult height is already achieved — only about 15% – 20% remains to be gained. This means that time is of the essence for those with idiopathic short stature (ISS), or children whose height is significantly below the average for their age and sex but without a readily identifiable medical...
Share
A growing body of research reveals that growth hormone (GH), long known for its role in growth and development, may have a darker side — one that could be manipulated for therapeutic benefit in cancer. A comprehensive review published in Endocrine Reviews spotlights the role of GH in cancer development and progression and evaluates the...
Share
Boys and girls may equally have multiple pituitary hormone deficiencies across all levels of peak growth hormone values, according to a study recently published in Clinical Endocrinology. The paper, by Rohan K. Henry, MD, MS, et al., outlines reported biases which have long been published regarding the male predominance in patients referred to pediatric endocrinology...
Share
The first global phase 2 study of vosoritide showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to a paper recently published in eClinicalMedicine. The clinical trial is funded by BioMarin. Researchers led by Andrew Dauber, MD, chief of Endocrinology at Children’s...
Share
On the 20th anniversary of the U.S. Food and Drug Administration’s approval of growth hormone (GH) treatment for idiopathic short stature (ISS), Adda Grimberg, MD, and Colin P. Hawkes, MD, PhD, both of the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, published a mini-review in The Journal...
Share
Childhood cancer patients and survivors are at increased risk for growth disturbances, for myriad reasons, and it is important to periodically monitor their growth, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Tomoko Yoshida, MD, PhD, and Angela Delaney, MD, both of St. Jude Children’s Research Hospital in Memphis,...
Share
The increase in free insulin-like growth factor (IGF)-I levels in prepubertal children with Prader-Willi Syndrome (PWS) treated with exogenous growth hormone (GH) could be caused by increased pregnancy-associated plasma protein A (PAPP-A, PAPP-A2) levels and a reduction in stanniocalcins (STC-1, STC-2), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism....
Share
Lonapegsomatropin, a once-weekly prodrug of somatropin, can help children in Tanner Stages 3-5 maintain consistent height standard deviation scores (SDS) without an increase in the mean dose, according to a study presented at ENDO 2023. Ascendis Pharma is marketing the drug as TransCon hGH. Researchers led by Paul Hofman, MD, FRACP, of the Liggins Institute...
